|
Therapy Area
High blood pressure.
|
|
In phase
In the process of entering into preclinical optimization phase. |
Competitive edge
Blood pressure reduction in combination with a potentially positive effect on target organs such as heart and kidney. |
Project data
- Three series available for optimization, all with highly potent start molecules (NDA-application for Aliskirer filed with the FDA in April 2006, Novartis hopes to take approximately 10% of a global market worth approximately USD 30 bn)
|
Main products 2006
(NDA-application for Aliskiren filed with the FDA in April 2006, Novartis hopes to take approximately 10% of a global market worth approximately usd 30 bn)
|
|
|
